Savalan Babapoor-Farrokhran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Savalan Babapoor-Farrokhran has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Aman Amanullah
Division of Cardiology, Department of Medicine, Albert Einstein Medical Center, 5501 Old York Road Unit 3, Philadelphia, PA 19141, USA
6 shared publicationsDeanna Gill
Department of Medicine, Emory University School of Medicine, Atlanta, USA
6 shared publicationsJafar Alzubi
Department of Medicine, Division of Cardiology, Einstein Medical Center, Philadelphia, PA, USA
5 shared publicationsSumeet K. Mainigi
Department of Medicine, Division of Cardiology, Einstein Medical Center, Philadelphia, PA, USA
5 shared publicationsRoozbeh Tarighati Rasekhi
Department of Neurology, SUNY Upstate, Syracuse, NY, 13210, USA
4 shared publicationsZachary Port
Department of Medicine, Division of Cardiology, Einstein Medical Center, Philadelphia, PA, USA
4 shared publications
Latest Publications
- Open Access
- 8 November 2023
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 66 (2) , 68-71
COVID-19 Can Unveil Brugada: A Rare Case
Brugada syndrome (BRS) is a channelopathy with three characteristic electrocardiogram patterns and an increased risk of sudden cardiac death (SCD), in the absence of gross structural heart disease. Fever is shown to precipitate ventricular arrhythmias in patients with BRS. Here, we report a rare case of Brugada pattern in a patient with Coronavirus Disease 2019 (COVID-19) without fever. A baseline ECG should be considered for patients with COVID-19, even in the absence of fever. COVID-19 by itself may be a factor that can induce Brugada pattern ECGs.
- 8 November 2023
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 66 (2) , 68-71
Open AccessCOVID-19 Can Unveil Brugada: A Rare Case
Brugada syndrome (BRS) is a channelopathy with three characteristic electrocardiogram patterns and an increased risk of sudden cardiac death (SCD), in the absence of gross structural heart disease. Fever is shown to precipitate ventricular arrhythmias in patients with BRS. Here, we report a rare case of Brugada pattern in a patient with Coronavirus Disease 2019 (COVID-19) without fever. A baseline ECG should be considered for patients with COVID-19, even in the absence of fever. COVID-19 by itself may be a factor that can induce Brugada pattern ECGs.
- Open Access
- 26 February 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (5) , 1666-1670
A rare case of primary adult cardiac rhabdomyosarcoma with lower extremity metastasis
- 26 February 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (5) , 1666-1670
Open AccessA rare case of primary adult cardiac rhabdomyosarcoma with lower extremity metastasis
- Open Access
- 1 July 2021
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 12 (7) , 4590-4593
Utility of High-frequency Jet Ventilation in Atrial Fibrillation Ablation
Utility of High-frequency Jet Ventilation in Atrial Fibrillation Ablation
- 1 July 2021
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 12 (7) , 4590-4593
Open AccessUtility of High-frequency Jet Ventilation in Atrial Fibrillation Ablation
Utility of High-frequency Jet Ventilation in Atrial Fibrillation Ablation
- 25 June 2021
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 3 (10) , 2088-2092
Impact of COVID-19 on Heart Failure Hospitalizations
The Novel Coronavirus Disease 2019 (COVID-19) pandemic has transformed individual lives and societal framework on a global scale, and in no other sector is this more evident than healthcare. Herein, we aim to describe the impact of the current COVID-19 pandemic and its associated restrictions on heart failure (HF) admissions. In this retrospective cohort study, we obtained administrative data for patients with a primary discharge diagnosis of HF (identified by ICD-10 code) with discharge dates ranging from January 2019 to November 2020. The study is comprised of 2 distinct sub-cohorts: HF admissions during the COVID-19 pandemic (case) period from March 2020 to October 2020 and corresponding control period during the previous year (March 2019 to December 2019). Primary outcome analysis involved comparison of total and daily HF admissions and secondary outcomes included hospital Length of Stay (LOS) and 30-day readmissions. The number of total HF admissions and average daily admissions were significantly lower in 2020 compared to 2019 (774 vs. 864; p < 0.001 and 3.17 vs. 3.53 days; p < 0.001), respectively. Average length of stay was significantly higher between March and October 2020 relative to the same months in 2019 (6.05 vs. 5.25 days; p < 0.001). Thirty-day readmission rates were also significantly higher in March–October 2020 compared to the same months in 2019 (20.6% vs. 19.1%; p < 0.001). During the pandemic, both readmission rates and length of stay for HF-related admissions were significantly impacted. The COVID-19 pandemic significantly impacted HF-related admissions as well as associated LOS and 30-day readmissions. High-risk patients should be identified carefully, and timely and appropriate treatment should be provided.
- 25 June 2021
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 3 (10) , 2088-2092
Impact of COVID-19 on Heart Failure Hospitalizations
The Novel Coronavirus Disease 2019 (COVID-19) pandemic has transformed individual lives and societal framework on a global scale, and in no other sector is this more evident than healthcare. Herein, we aim to describe the impact of the current COVID-19 pandemic and its associated restrictions on heart failure (HF) admissions. In this retrospective cohort study, we obtained administrative data for patients with a primary discharge diagnosis of HF (identified by ICD-10 code) with discharge dates ranging from January 2019 to November 2020. The study is comprised of 2 distinct sub-cohorts: HF admissions during the COVID-19 pandemic (case) period from March 2020 to October 2020 and corresponding control period during the previous year (March 2019 to December 2019). Primary outcome analysis involved comparison of total and daily HF admissions and secondary outcomes included hospital Length of Stay (LOS) and 30-day readmissions. The number of total HF admissions and average daily admissions were significantly lower in 2020 compared to 2019 (774 vs. 864; p < 0.001 and 3.17 vs. 3.53 days; p < 0.001), respectively. Average length of stay was significantly higher between March and October 2020 relative to the same months in 2019 (6.05 vs. 5.25 days; p < 0.001). Thirty-day readmission rates were also significantly higher in March–October 2020 compared to the same months in 2019 (20.6% vs. 19.1%; p < 0.001). During the pandemic, both readmission rates and length of stay for HF-related admissions were significantly impacted. The COVID-19 pandemic significantly impacted HF-related admissions as well as associated LOS and 30-day readmissions. High-risk patients should be identified carefully, and timely and appropriate treatment should be provided.
- 11 February 2021
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 476 (6) , 2283-2293
Atrial fibrillation: the role of hypoxia-inducible factor-1-regulated cytokines
Atrial fibrillation (AF) is a common arrhythmia that has major morbidity and mortality. Hypoxia plays an important role in AF initiation and maintenance. Hypoxia-inducible factor (HIF), the master regulator of oxygen homeostasis in cells, plays a fundamental role in the regulation of multiple chemokines and cytokines that are involved in different physiological and pathophysiological pathways. HIF is also involved in the pathophysiology of AF induction and propagation mostly through structural remodeling such as fibrosis; however, some of the cytokines discussed have even been implicated in electrical remodeling of the atria. In this article, we highlight the association between HIF and some of its related cytokines with AF. Additionally, we provide an overview of the potential diagnostic benefits of using the mentioned cytokines as AF biomarkers. Research discussed in this review suggests that the expression of these cytokines may correlate with patients who are at an increased risk of developing AF. Furthermore, cytokines that are elevated in patients with AF can assist clinicians in the diagnosis of suspect paroxysmal AF patients. Interestingly, some of the cytokines have been elevated specifically when AF is associated with a hypercoagulable state, suggesting that they could be helpful in the clinician’s and patient’s decision to begin anticoagulation. Finally, more recent research has demonstrated the promise of targeting these cytokines for the treatment of AF. While still in its early stages, tools such as neutralizing antibodies have proved to be efficacious in targeting the HIF pathway and treating or preventing AF.
- 11 February 2021
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 476 (6) , 2283-2293
Atrial fibrillation: the role of hypoxia-inducible factor-1-regulated cytokines
Atrial fibrillation (AF) is a common arrhythmia that has major morbidity and mortality. Hypoxia plays an important role in AF initiation and maintenance. Hypoxia-inducible factor (HIF), the master regulator of oxygen homeostasis in cells, plays a fundamental role in the regulation of multiple chemokines and cytokines that are involved in different physiological and pathophysiological pathways. HIF is also involved in the pathophysiology of AF induction and propagation mostly through structural remodeling such as fibrosis; however, some of the cytokines discussed have even been implicated in electrical remodeling of the atria. In this article, we highlight the association between HIF and some of its related cytokines with AF. Additionally, we provide an overview of the potential diagnostic benefits of using the mentioned cytokines as AF biomarkers. Research discussed in this review suggests that the expression of these cytokines may correlate with patients who are at an increased risk of developing AF. Furthermore, cytokines that are elevated in patients with AF can assist clinicians in the diagnosis of suspect paroxysmal AF patients. Interestingly, some of the cytokines have been elevated specifically when AF is associated with a hypercoagulable state, suggesting that they could be helpful in the clinician’s and patient’s decision to begin anticoagulation. Finally, more recent research has demonstrated the promise of targeting these cytokines for the treatment of AF. While still in its early stages, tools such as neutralizing antibodies have proved to be efficacious in targeting the HIF pathway and treating or preventing AF.
- 3 February 2021
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 21 (6) , 490-493
Peripheral Administration of Nitroglycerin in Pulseless Ventricular Tachycardia due to Cocaine-Induced Coronary Vasospasm
Cocaine use accounts for 40% of the annual drug use related emergency department visits in the United States. Cocaine use is hence recognized as a major health problem. Cocaine blocks the presynaptic reuptake of norepinephrine and dopamine. The resulting increased adrenergic activity leads to vasoconstriction. Additionally, via various mechanisms, cocaine leads to a prothrombotic state and increases myocardial demand. Cocaine can cause coronary vasospasm and is therefore, associated with acute myocardial injury even in the absence of pre-existing atherosclerotic coronary artery disease. Nitroglycerin has a class 1C indication by the ACCF/AHA guidelines for patients with ST-segment elevation or depression that accompanies ischemic chest discomfort in the setting of cocaine use. It has been shown to reverse cocaine-induced coronary vasospasm and chest pain. In this case report, for the first time, we discuss how intravenous administration of high dose nitroglycerin to a patient in pulseless ventricular tachycardia with angiographically confirmed vasospasm induced by cocaine resulted in return of spontaneous circulation.
- 3 February 2021
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 21 (6) , 490-493
Peripheral Administration of Nitroglycerin in Pulseless Ventricular Tachycardia due to Cocaine-Induced Coronary Vasospasm
Cocaine use accounts for 40% of the annual drug use related emergency department visits in the United States. Cocaine use is hence recognized as a major health problem. Cocaine blocks the presynaptic reuptake of norepinephrine and dopamine. The resulting increased adrenergic activity leads to vasoconstriction. Additionally, via various mechanisms, cocaine leads to a prothrombotic state and increases myocardial demand. Cocaine can cause coronary vasospasm and is therefore, associated with acute myocardial injury even in the absence of pre-existing atherosclerotic coronary artery disease. Nitroglycerin has a class 1C indication by the ACCF/AHA guidelines for patients with ST-segment elevation or depression that accompanies ischemic chest discomfort in the setting of cocaine use. It has been shown to reverse cocaine-induced coronary vasospasm and chest pain. In this case report, for the first time, we discuss how intravenous administration of high dose nitroglycerin to a patient in pulseless ventricular tachycardia with angiographically confirmed vasospasm induced by cocaine resulted in return of spontaneous circulation.
- 1 February 2021
- Published by Elsevier in Life Sciences
- Vol. 266, 118823
How transforming growth factor contributes to atrial fibrillation?
- 1 February 2021
- Published by Elsevier in Life Sciences
- Vol. 266, 118823
How transforming growth factor contributes to atrial fibrillation?
- Open Access
- 1 January 2021
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 17 (1) , 71-72
Fibromuscular Dysplasia Involving the Coronary Arteries
- 1 January 2021
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 17 (1) , 71-72
Open AccessFibromuscular Dysplasia Involving the Coronary Arteries
- Open Access
- 1 December 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (6) , 1-6
Wide unroofed coronary sinus and cryptogenic stroke: a case report
Background : Unroofed coronary sinus (UCS) is a rare congenital cardiac anomaly in which there is complete or partial absence of the roof of the coronary sinus (CS) resulting in a communication between the right and left atria. There are four types of UCS described in the literature. While usually asymptomatic and discovered incidentally on imaging, UCS can be the source of a brain abscess or paradoxical embolism. Case summary : A 62-year-old gentleman presented to the emergency department with sudden onset of right-sided weakness and subsequent unresponsiveness. His brain computed tomography (CT) was consistent with left-sided stroke. Transthoracic echocardiography was remarkable for a dilated CS and an agitated saline study was suggestive of an UCS. A gated cardiac CT with coronary angiography confirmed a wide communication between the CS and left atrium. Right heart catheterization did not show evidence of left to right shunt. He had no abnormal rhythm on telemetry monitoring throughout his hospital stay. Discussion : Unroofed coronary sinus is the least prevalent form of an atrial septal defect. Unroofed coronary sinus is usually asymptomatic and is diagnosed incidentally in imaging studies, however, it should be suspected in patients with cerebral emboli or evidence of left to right shunt with unexplained arterial desaturation. Transthoracic echocardiography is the most widely used imaging modality for the diagnosis of UCS but is limited in its ability to visualize the posterior cardiac structures such as the CS and pulmonary veins. Gated cardiac CT is a great diagnostic tool for UCS.
- 1 December 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (6) , 1-6
Open AccessWide unroofed coronary sinus and cryptogenic stroke: a case report
Background : Unroofed coronary sinus (UCS) is a rare congenital cardiac anomaly in which there is complete or partial absence of the roof of the coronary sinus (CS) resulting in a communication between the right and left atria. There are four types of UCS described in the literature. While usually asymptomatic and discovered incidentally on imaging, UCS can be the source of a brain abscess or paradoxical embolism. Case summary : A 62-year-old gentleman presented to the emergency department with sudden onset of right-sided weakness and subsequent unresponsiveness. His brain computed tomography (CT) was consistent with left-sided stroke. Transthoracic echocardiography was remarkable for a dilated CS and an agitated saline study was suggestive of an UCS. A gated cardiac CT with coronary angiography confirmed a wide communication between the CS and left atrium. Right heart catheterization did not show evidence of left to right shunt. He had no abnormal rhythm on telemetry monitoring throughout his hospital stay. Discussion : Unroofed coronary sinus is the least prevalent form of an atrial septal defect. Unroofed coronary sinus is usually asymptomatic and is diagnosed incidentally in imaging studies, however, it should be suspected in patients with cerebral emboli or evidence of left to right shunt with unexplained arterial desaturation. Transthoracic echocardiography is the most widely used imaging modality for the diagnosis of UCS but is limited in its ability to visualize the posterior cardiac structures such as the CS and pulmonary veins. Gated cardiac CT is a great diagnostic tool for UCS.
- Open Access
- 20 October 2020
- Published by Rivera Publications Inc. in Annals of Cardiology
- Vol. 1 (1)
Multiple Arrhythmias in COVID-19 Patients: A Case Series
Extra-pulmonary manifestations of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection such as cardiovascular complications have been reported and previous case reports have documented evidence of myocardial damage. Currently, very few case reports of the arrhythmias associated with Coronavirus Disease 2019 [COVID-19] exist. In this case series, we demonstrate two cases of critically ill COVID-19 patients with cardiac rhythm abnormalities that might be a direct or indirect consequence of this infection. Each of the patients experienced a variety of cardiac rhythm abnormalities. None of the patients had any record of cardiac rhythm abnormalities prior to admission. The unique point of these cases is the multiple dysrhythmias in the same patients that have not been reported previously. We demonstrated that critically ill COVID-19 patients develop different arrhythmias ranging from sinus tachycardia, bradycardia, atrial fibrillation, supraventricular tachycardia, and non-sustained ventricular tachycardia. Non-sustained monomorphic ventricular tachycardia was the most common arrhythmia in the two cases despite normalization of electrolyte imbalances and avoidance of QTc prolonging agents.
- 20 October 2020
- Published by Rivera Publications Inc. in Annals of Cardiology
- Vol. 1 (1)
Open AccessMultiple Arrhythmias in COVID-19 Patients: A Case Series
Extra-pulmonary manifestations of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection such as cardiovascular complications have been reported and previous case reports have documented evidence of myocardial damage. Currently, very few case reports of the arrhythmias associated with Coronavirus Disease 2019 [COVID-19] exist. In this case series, we demonstrate two cases of critically ill COVID-19 patients with cardiac rhythm abnormalities that might be a direct or indirect consequence of this infection. Each of the patients experienced a variety of cardiac rhythm abnormalities. None of the patients had any record of cardiac rhythm abnormalities prior to admission. The unique point of these cases is the multiple dysrhythmias in the same patients that have not been reported previously. We demonstrated that critically ill COVID-19 patients develop different arrhythmias ranging from sinus tachycardia, bradycardia, atrial fibrillation, supraventricular tachycardia, and non-sustained ventricular tachycardia. Non-sustained monomorphic ventricular tachycardia was the most common arrhythmia in the two cases despite normalization of electrolyte imbalances and avoidance of QTc prolonging agents.